3 Houston innovators to know this week

who's who

This week's innovators to know are Sean Guerre of Innovate Energy, Carolyn Rodz of Hello Alice, and Aziz Gilani of Mercury Fund. Courtesy photos

From quickly making face masks to preparing meals for hospital workers, Houstonians everywhere are finding the best way for them to give back. For these three innovators to know this week, their way of giving back is helping startups navigate this unprecedented time.

Sean Guerre, managing director of Innovate Energy

Photo courtesy of Innovate Energy

The oil and gas industry is going through an unprecedented time. Never before have energy companies had to deal with such a large discrepancy between supply and demand, and COVID-19 closures is just the cherry on top. A victim of the situation is going to be early-stage energy tech startups. However, Guerre says he is seeing interest in startups that specialize in a specific type of technology.

"We're seeing a huge interest in autonomous, unmanned solutions," Guerre says on this week's episode of the Houston Innovators Podcast. "Anything in that remote, autonomous area that allows people to continue to do inspections, mapping, surveying, and all kinds of work that don't involve more people being involved in the process — we're seeing a real acceleration there."

Click here to read more.

Carolyn Rodz, CEO of Hello Alice

Courtesy of Hello Alice

While a bunch of companies are left idle with not much to do during the COVID-19-caused shutdown, Carolyn Rodz, CEO and co-founder of Houston-based Hello Alice, has been busier than ever. Her company, which provides digital resources for startups and small businesses, has kicked their operations into high gear.

Rodz and her team created a COVID-19 Business Center free for entrepreneurs to use, as well as announced emergency grants to businesses affected by COVID-19.

Click here to read more.

Aziz Gilani, managing director of Mercury Fund

Photo courtesy of Mercury Fund

The repercussions of the pandemic has forced Aziz Gilani to become an expert in the CARES Act in order to help Mercury Fund's portfolio companies, but Gilani has been more than willing to share his newfound expertise. He joined Rodz on a virtual panel hosted by Houston Exponential and the duo offered pertinent advice for Houston startups — especially in light of the lack of clarity in the quickly passed legislature.

"One of the challenges of the program is that it is being administered by the Small Business Administration, which traditionally hasn't worked with venture-backed and angel-backed companies," Gilani says, adding that now is the time to document everything and involve a lawyer to help you mitigate the act's details.

Click here to read more.

Sean Guerre of Innovate Energy joins the Houston Innovators Podcast to share how energy startups are especially challenged in the current climate. Photo courtesy of Innovate Energy

Early-stage energy tech startups to be hit hard by COVID-19 and flooded oil market, Houston expert says

HOUSTON INNOVATORS PODCAST EPISODE 26

The oil and gas industry has been hit with a double whammy of challenges with COVID-19 and its imminent recession, but the global industry was already facing an oversupply of oil — and now an even smaller demand.

One of this confluence of obstacles' victims is going to be early-stage energy tech startups, Sean Guerre, managing director of Innovate Energy, says on this week's episode of the Houston Innovators Podcast.

"When you think about what's happening in the oil downturn, unfortunately it's just a slice in huge uncertainty sandwich that we're all having to go through right now," Guerre says.

Not only is the pandemic unprecedented, but the cyclical energy industry hasn't faced a situation with so much discrepancy between supply and demand since the 1930s, which is a bit too far back to really take in any lessons learned.

Energy tech startups that are pre-funding and pre-pilots are going to struggle to get a foot in the door at bigger companies and aren't going to find much funding — both venture capital and corporate venture are down, Guerre says. He recommends really focusing on messaging moving forward — startups need to pitch cost-saving and efficient solutions.

"You've got to make sure your message fits the market," Guerre says. "What was working four weeks ago is probably not what you're going forth with now."

Innovate Energy, which produces online content for the advancement of energy tech and innovation, has seen a rise in interest in digital and unmanned solutions like robotics and industrial virtual reality.

"We're seeing a huge interest in autonomous, unmanned solutions," Guerre says. "Anything in that remote, autonomous area that allows people to continue to do inspections, mapping, surveying, and all kinds of work that don't involve more people being involved in the process — we're seeing a real acceleration there."

Startups are also challenged with a lack of events and networking opportunities with the COVID-19 mandates to stay at home and social distance. Guerre, who founded Stone Fort Group to put on virtual and in-person programming, says it's a new burden on event holders to use technology to optimize their events for the happenstance and socialization that happens at in-person events.

"How do we actually help people connect who wouldn't normally would have connected if they hadn't been sitting next to each other in a general session or waiting in line at the coffee line," he says on the show.

Guerre shares his thoughts on the state of energy moving forward, and how key these virtual events are on the podcast. Listen to the full episode below — or wherever you get your podcasts — and subscribe for weekly episodes.



Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings